The critical role that the Ubiquitin Proteasome Pathway (UPP) plays in cellular signaling coupled with increasing validation of the therapeutic potential of targets in this pathway is accelerating interest in this field among both academic and pharmaceutical researchers.

Launched in collaboration with Sir Philip Cohen, Director of the Scottish Institute for Cell Signaling's Protein Ubiquitylation Unit (PUU) and the Medical Research Council's Protein Phosphorylation Unit at the University of Dundee, Ubiquigent offers highest quality Ubiquitin Proteasome Pathway reagents and related drug discovery services to the academic and pharmaceutical research communities. Ubiquigent's research and product development laboratories are located adjacent to the PUU.

Sir Philip Cohen and the founders of Ubiquigent have an extensive background in providing cutting-edge reagents and drug discovery services in the field of kinases and phosphorylation. By employing our experience and expertise, we aim to support and accelerate the field of UPP research with our product and service offering. Learn More »